Poisoning by, adverse effect of and underdosing of nonopioid analgesics, antipyretics and antirheumatics (T39)

Browse all the diagnosis codes used for poisoning by, adverse effect of and underdosing of nonopioid analgesics, antipyretics and antirheumatics (t39). For easy navigation, the diagnosis codes are sorted in alphabetical order and grouped by sections. Each section is clearly marked with its description, and the corresponding three-digit code range. This format makes it simple to browse diagnosis codes in this chapter or section and find what you're looking for. We've also added green checkmark icons to label billable codes, and red warning icons for non-billable ones. This makes it easy to identify which codes can be billed.

Clinical Information

Acetaminophen - Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.

Aminopyrine - A pyrazolone with analgesic, anti-inflammatory, and antipyretic properties but has risk of AGRANULOCYTOSIS. A breath test with 13C-labeled aminopyrine has been used as a non-invasive measure of CYTOCHROME P-450 metabolic activity in LIVER FUNCTION TESTS.

Aminopyrine N-Demethylase - A pyrazolone with analgesic, anti-inflammatory, and antipyretic properties but has risk of AGRANULOCYTOSIS. A breath test with 13C-labeled aminopyrine has been used as a non-invasive measure of CYTOCHROME P-450 metabolic activity in LIVER FUNCTION TESTS.

Antipyrine - An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29)

Arylsulfotransferase - A sulfotransferase that catalyzes the sulfation of a phenol in the presence of 3'-phosphoadenylylsulfate as sulfate donor to yield an aryl sulfate and adenosine 3',5'-bisphosphate. A number of aromatic compounds can act as acceptors; however, organic hydroxylamines are not substrates. Sulfate conjugation by this enzyme is a major pathway for the biotransformation of phenolic and catechol drugs as well as neurotransmitters. EC 2.8.2.1.

Auranofin - An oral chrysotherapeutic agent for the treatment of rheumatoid arthritis. Its exact mechanism of action is unknown, but it is believed to act via immunological mechanisms and alteration of lysosomal enzyme activity. Its efficacy is slightly less than that of injected gold salts, but it is better tolerated, and side effects which occur are potentially less serious.

Aurothioglucose - A thioglucose derivative used as an antirheumatic and experimentally to produce obesity in animals.

Carboxylesterase - Carboxylesterase is a serine-dependent esterase with wide substrate specificity. The enzyme is involved in the detoxification of XENOBIOTICS and the activation of ester and of amide PRODRUGS.

Clonixin - Anti-inflammatory analgesic.

Cytochrome P-450 CYP1A2 - A cytochrome P450 enzyme subtype that has specificity for relatively planar heteroaromatic small molecules, such as CAFFEINE and ACETAMINOPHEN.

Diclofenac - A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.

Diflunisal - A salicylate derivative and anti-inflammatory analgesic with actions and side effects similar to those of ASPIRIN.

Dipyrone - A drug that has analgesic, anti-inflammatory, and antipyretic properties. It is the sodium sulfonate of AMINOPYRINE.

Etodolac - A non-steroidal anti-inflammatory agent and cyclooxygenase-2 (COX-2) inhibitor with potent analgesic and anti-arthritic properties. It has been shown to be effective in the treatment of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; and in the alleviation of postoperative pain (PAIN, POSTOPERATIVE).

Fenoprofen - A propionic acid derivative that is used as a non-steroidal anti-inflammatory agent.

Feprazone - A pyrazole that has analgesic, anti-inflammatory, and antipyretic properties. It has been used in mild to moderate pain, fever, and inflammation associated with musculoskeletal and joint disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p15)

Flufenamic Acid - An anthranilic acid derivative with analgesic, anti-inflammatory, and antipyretic properties. It is used in musculoskeletal and joint disorders and administered by mouth and topically. (From Martindale, The Extra Pharmacopoeia, 30th ed, p16)

Flurbiprofen - An anti-inflammatory analgesic and antipyretic of the phenylalkynoic acid series. It has been shown to reduce bone resorption in periodontal disease by inhibiting CARBONIC ANHYDRASE.

Glafenine - An anthranilic acid derivative with analgesic properties used for the relief of all types of pain.

Ibuprofen - A non-steroidal anti-inflammatory agent with analgesic, antipyretic, and anti-inflammatory properties

Indomethacin - A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.

Jamaica - An island in the Greater Antilles in the West Indies. Its capital is Kingston. It was discovered in 1494 by Columbus and was a Spanish colony 1509-1655 until captured by the English. Its flourishing slave trade was abolished in the 19th century. It was a British colony 1655-1958 and a territory of the West Indies Federation 1958-62. It achieved full independence in 1962. The name is from the Arawak Xaymaca, rich in springs or land of springs. (From Webster's New Geographical Dictionary, 1988, p564 & Room, Brewer's Dictionary of Names, 1992, p267)

Ketoprofen - An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis.

Ketorolac - A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed)

Ketorolac Tromethamine - A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is a non-steroidal anti-inflammatory agent used for analgesia for postoperative pain and inhibits cyclooxygenase activity.

Meclofenamic Acid - A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis.

Mefenamic Acid - A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.

Meptazinol - A narcotic antagonist with analgesic properties. It is used for the control of moderate to severe pain.

Nabumetone - A butanone non-steroidal anti-inflammatory drug and cyclooxygenase-2 (COX2) inhibitor that is used in the management of pain associated with OSTEOARTHRITIS and RHEUMATOID ARTHRITIS.

Naproxen - An anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout.

Nefopam - Non-narcotic analgesic chemically similar to ORPHENADRINE. Its mechanism of action is unclear. It is used for the relief of acute and chronic pain. (From Martindale, The Extra Pharmacopoeia, 30th ed, p26)

Oxaprozin - An oxazole-propionic acid derivative, cyclooxygenase inhibitor, and non-steroidal anti-inflammatory drug that is used in the treatment of pain and inflammation associated with of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; and ARTHRITIS, JUVENILE.

Oxyphenbutazone - A non-steroidal anti-inflammatory drug. Oxyphenbutazone eyedrops have been used abroad in the management of postoperative ocular inflammation, superficial eye injuries, and episcleritis. (From AMA, Drug Evaluations Annual, 1994, p2000) It had been used by mouth in rheumatic disorders such as ankylosing spondylitis, osteoarthritis, and rheumatoid arthritis but such use is no longer considered justified owing to the risk of severe hematological adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p27)

Phenacetin - A phenylacetamide that was formerly used in ANALGESICS but nephropathy and METHEMOGLOBINEMIA led to its withdrawal from the market. (From Smith and Reynard, Textbook of Pharmacology,1991, p431)

Phenazopyridine - A local anesthetic that has been used in urinary tract disorders. Its use is limited by problems with toxicity (primarily blood disorders) and potential carcinogenicity.

Phenylbutazone - A butyl-diphenyl-pyrazolidinedione that has anti-inflammatory, antipyretic, and analgesic activities. It has been used in ANKYLOSING SPONDYLITIS; RHEUMATOID ARTHRITIS; and REACTIVE ARTHRITIS.

Piroxicam - A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily.

Salicylates - The salts or esters of salicylic acids, or salicylate esters of an organic acid. Some of these have analgesic, antipyretic, and anti-inflammatory activities by inhibiting prostaglandin synthesis.

Smilax - A plant genus of the family SMILACACEAE. Members contain smiglasides (phenylpropanoid glycosides) and steroidal saponins. Commercially it is sometimes adulterated with HEMIDESMUS, which would affect experimental results. Drinks called sarsaparilla and root beer have been prepared from the Smilaz ornata (Jamaican sarsaparilla) and SASSAFRAS.

Sulindac - A sulfinylindene derivative prodrug whose sulfinyl moiety is converted in vivo to an active NSAID analgesic. Specifically, the prodrug is converted by liver enzymes to a sulfide which is excreted in the bile and then reabsorbed from the intestine. This helps to maintain constant blood levels with reduced gastrointestinal side effects.

Sumatriptan - A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.

Suprofen - An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It inhibits prostaglandin synthesis and has been proposed as an anti-arthritic.

Tolmetin - A non-steroidal anti-inflammatory agent (ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL) similar in mode of action to INDOMETHACIN.

Instructional Notations

7th Character Note

Certain ICD-10-CM categories have applicable 7th characters. The applicable 7th character is required for all codes within the category, or as the notes in the Tabular List instruct. The 7th character must always be the 7th character in the data field. If a code that requires a 7th character is not 6 characters, a placeholder X must be used to fill in the empty characters.

  • The appropriate 7th character is to be added to each code from category T39

7th Character

Indicates that a seventh character is to be assigned to codes in a subcategory.

  • A - initial encounter
  • D - subsequent encounter
  • S - sequela
  • Injury, poisoning and certain other consequences of external causes (S00–T88)

    • Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances (T36-T50)

        • Poisoning by, adverse effect of and underdosing of nonopioid analgesics, antipyretics and antirheumatics (T39)

        • T39 Poisoning by, adverse effect of and underdosing of nonopioid analgesics, antipyretics and antirheumatics
        • T39.0 Poisoning by, adverse effect of and underdosing of salicylates
        • T39.01 Poisoning by, adverse effect of and underdosing of aspirin
        • T39.011 Poisoning by aspirin, accidental (unintentional)
        • T39.011A Poisoning by aspirin, accidental (unintentional), initial encounter
        • T39.011D Poisoning by aspirin, accidental (unintentional), subsequent encounter
        • T39.011S Poisoning by aspirin, accidental (unintentional), sequela
        • T39.012 Poisoning by aspirin, intentional self-harm
        • T39.012A Poisoning by aspirin, intentional self-harm, initial encounter
        • T39.012D Poisoning by aspirin, intentional self-harm, subsequent encounter
        • T39.012S Poisoning by aspirin, intentional self-harm, sequela
        • T39.013 Poisoning by aspirin, assault
        • T39.013A Poisoning by aspirin, assault, initial encounter
        • T39.013D Poisoning by aspirin, assault, subsequent encounter
        • T39.013S Poisoning by aspirin, assault, sequela
        • T39.014 Poisoning by aspirin, undetermined
        • T39.014A Poisoning by aspirin, undetermined, initial encounter
        • T39.014D Poisoning by aspirin, undetermined, subsequent encounter
        • T39.014S Poisoning by aspirin, undetermined, sequela
        • T39.015 Adverse effect of aspirin
        • T39.015A Adverse effect of aspirin, initial encounter
        • T39.015D Adverse effect of aspirin, subsequent encounter
        • T39.015S Adverse effect of aspirin, sequela
        • T39.016 Underdosing of aspirin
        • T39.016A Underdosing of aspirin, initial encounter
        • T39.016D Underdosing of aspirin, subsequent encounter
        • T39.016S Underdosing of aspirin, sequela
        • T39.09 Poisoning by, adverse effect of and underdosing of other salicylates
        • T39.091 Poisoning by salicylates, accidental (unintentional)
        • T39.091A Poisoning by salicylates, accidental (unintentional), initial encounter
        • T39.091D Poisoning by salicylates, accidental (unintentional), subsequent encounter
        • T39.091S Poisoning by salicylates, accidental (unintentional), sequela
        • T39.092 Poisoning by salicylates, intentional self-harm
        • T39.092A Poisoning by salicylates, intentional self-harm, initial encounter
        • T39.092D Poisoning by salicylates, intentional self-harm, subsequent encounter
        • T39.092S Poisoning by salicylates, intentional self-harm, sequela
        • T39.093 Poisoning by salicylates, assault
        • T39.093A Poisoning by salicylates, assault, initial encounter
        • T39.093D Poisoning by salicylates, assault, subsequent encounter
        • T39.093S Poisoning by salicylates, assault, sequela
        • T39.094 Poisoning by salicylates, undetermined
        • T39.094A Poisoning by salicylates, undetermined, initial encounter
        • T39.094D Poisoning by salicylates, undetermined, subsequent encounter
        • T39.094S Poisoning by salicylates, undetermined, sequela
        • T39.095 Adverse effect of salicylates
        • T39.095A Adverse effect of salicylates, initial encounter
        • T39.095D Adverse effect of salicylates, subsequent encounter
        • T39.095S Adverse effect of salicylates, sequela
        • T39.096 Underdosing of salicylates
        • T39.096A Underdosing of salicylates, initial encounter
        • T39.096D Underdosing of salicylates, subsequent encounter
        • T39.096S Underdosing of salicylates, sequela
        • T39.1 Poisoning by, adverse effect of and underdosing of 4-Aminophenol derivatives
        • T39.1X Poisoning by, adverse effect of and underdosing of 4-Aminophenol derivatives
        • T39.1X1 Poisoning by 4-Aminophenol derivatives, accidental (unintentional)
        • T39.1X1A Poisoning by 4-Aminophenol derivatives, accidental (unintentional), initial encounter
        • T39.1X1D Poisoning by 4-Aminophenol derivatives, accidental (unintentional), subsequent encounter
        • T39.1X1S Poisoning by 4-Aminophenol derivatives, accidental (unintentional), sequela
        • T39.1X2 Poisoning by 4-Aminophenol derivatives, intentional self-harm
        • T39.1X2A Poisoning by 4-Aminophenol derivatives, intentional self-harm, initial encounter
        • T39.1X2D Poisoning by 4-Aminophenol derivatives, intentional self-harm, subsequent encounter
        • T39.1X2S Poisoning by 4-Aminophenol derivatives, intentional self-harm, sequela
        • T39.1X3 Poisoning by 4-Aminophenol derivatives, assault
        • T39.1X3A Poisoning by 4-Aminophenol derivatives, assault, initial encounter
        • T39.1X3D Poisoning by 4-Aminophenol derivatives, assault, subsequent encounter
        • T39.1X3S Poisoning by 4-Aminophenol derivatives, assault, sequela
        • T39.1X4 Poisoning by 4-Aminophenol derivatives, undetermined
        • T39.1X4A Poisoning by 4-Aminophenol derivatives, undetermined, initial encounter
        • T39.1X4D Poisoning by 4-Aminophenol derivatives, undetermined, subsequent encounter
        • T39.1X4S Poisoning by 4-Aminophenol derivatives, undetermined, sequela
        • T39.1X5 Adverse effect of 4-Aminophenol derivatives
        • T39.1X5A Adverse effect of 4-Aminophenol derivatives, initial encounter
        • T39.1X5D Adverse effect of 4-Aminophenol derivatives, subsequent encounter
        • T39.1X5S Adverse effect of 4-Aminophenol derivatives, sequela
        • T39.1X6 Underdosing of 4-Aminophenol derivatives
        • T39.1X6A Underdosing of 4-Aminophenol derivatives, initial encounter
        • T39.1X6D Underdosing of 4-Aminophenol derivatives, subsequent encounter
        • T39.1X6S Underdosing of 4-Aminophenol derivatives, sequela
        • T39.2 Poisoning by, adverse effect of and underdosing of pyrazolone derivatives
        • T39.2X Poisoning by, adverse effect of and underdosing of pyrazolone derivatives
        • T39.2X1 Poisoning by pyrazolone derivatives, accidental (unintentional)
        • T39.2X1A Poisoning by pyrazolone derivatives, accidental (unintentional), initial encounter
        • T39.2X1D Poisoning by pyrazolone derivatives, accidental (unintentional), subsequent encounter
        • T39.2X1S Poisoning by pyrazolone derivatives, accidental (unintentional), sequela
        • T39.2X2 Poisoning by pyrazolone derivatives, intentional self-harm
        • T39.2X2A Poisoning by pyrazolone derivatives, intentional self-harm, initial encounter
        • T39.2X2D Poisoning by pyrazolone derivatives, intentional self-harm, subsequent encounter
        • T39.2X2S Poisoning by pyrazolone derivatives, intentional self-harm, sequela
        • T39.2X3 Poisoning by pyrazolone derivatives, assault
        • T39.2X3A Poisoning by pyrazolone derivatives, assault, initial encounter
        • T39.2X3D Poisoning by pyrazolone derivatives, assault, subsequent encounter
        • T39.2X3S Poisoning by pyrazolone derivatives, assault, sequela
        • T39.2X4 Poisoning by pyrazolone derivatives, undetermined
        • T39.2X4A Poisoning by pyrazolone derivatives, undetermined, initial encounter
        • T39.2X4D Poisoning by pyrazolone derivatives, undetermined, subsequent encounter
        • T39.2X4S Poisoning by pyrazolone derivatives, undetermined, sequela
        • T39.2X5 Adverse effect of pyrazolone derivatives
        • T39.2X5A Adverse effect of pyrazolone derivatives, initial encounter
        • T39.2X5D Adverse effect of pyrazolone derivatives, subsequent encounter
        • T39.2X5S Adverse effect of pyrazolone derivatives, sequela
        • T39.2X6 Underdosing of pyrazolone derivatives
        • T39.2X6A Underdosing of pyrazolone derivatives, initial encounter
        • T39.2X6D Underdosing of pyrazolone derivatives, subsequent encounter
        • T39.2X6S Underdosing of pyrazolone derivatives, sequela
        • T39.3 Poisoning by, adverse effect of and underdosing of other nonsteroidal anti-inflammatory drugs [NSAID]
        • T39.31 Poisoning by, adverse effect of and underdosing of propionic acid derivatives
        • T39.311 Poisoning by propionic acid derivatives, accidental (unintentional)
        • T39.311A Poisoning by propionic acid derivatives, accidental (unintentional), initial encounter
        • T39.311D Poisoning by propionic acid derivatives, accidental (unintentional), subsequent encounter
        • T39.311S Poisoning by propionic acid derivatives, accidental (unintentional), sequela
        • T39.312 Poisoning by propionic acid derivatives, intentional self-harm
        • T39.312A Poisoning by propionic acid derivatives, intentional self-harm, initial encounter
        • T39.312D Poisoning by propionic acid derivatives, intentional self-harm, subsequent encounter
        • T39.312S Poisoning by propionic acid derivatives, intentional self-harm, sequela
        • T39.313 Poisoning by propionic acid derivatives, assault
        • T39.313A Poisoning by propionic acid derivatives, assault, initial encounter
        • T39.313D Poisoning by propionic acid derivatives, assault, subsequent encounter
        • T39.313S Poisoning by propionic acid derivatives, assault, sequela
        • T39.314 Poisoning by propionic acid derivatives, undetermined
        • T39.314A Poisoning by propionic acid derivatives, undetermined, initial encounter
        • T39.314D Poisoning by propionic acid derivatives, undetermined, subsequent encounter
        • T39.314S Poisoning by propionic acid derivatives, undetermined, sequela
        • T39.315 Adverse effect of propionic acid derivatives
        • T39.315A Adverse effect of propionic acid derivatives, initial encounter
        • T39.315D Adverse effect of propionic acid derivatives, subsequent encounter
        • T39.315S Adverse effect of propionic acid derivatives, sequela
        • T39.316 Underdosing of propionic acid derivatives
        • T39.316A Underdosing of propionic acid derivatives, initial encounter
        • T39.316D Underdosing of propionic acid derivatives, subsequent encounter
        • T39.316S Underdosing of propionic acid derivatives, sequela
        • T39.39 Poisoning by, adverse effect of and underdosing of other nonsteroidal anti-inflammatory drugs [NSAID]
        • T39.391 Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], accidental (unintentional)
        • T39.391A Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], accidental (unintentional), initial encounter
        • T39.391D Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], accidental (unintentional), subsequent encounter
        • T39.391S Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], accidental (unintentional), sequela
        • T39.392 Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm
        • T39.392A Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm, initial encounter
        • T39.392D Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm, subsequent encounter
        • T39.392S Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm, sequela
        • T39.393 Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], assault
        • T39.393A Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], assault, initial encounter
        • T39.393D Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], assault, subsequent encounter
        • T39.393S Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], assault, sequela
        • T39.394 Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], undetermined
        • T39.394A Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], undetermined, initial encounter
        • T39.394D Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], undetermined, subsequent encounter
        • T39.394S Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], undetermined, sequela
        • T39.395 Adverse effect of other nonsteroidal anti-inflammatory drugs [NSAID]
        • T39.395A Adverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], initial encounter
        • T39.395D Adverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], subsequent encounter
        • T39.395S Adverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], sequela
        • T39.396 Underdosing of other nonsteroidal anti-inflammatory drugs [NSAID]
        • T39.396A Underdosing of other nonsteroidal anti-inflammatory drugs [NSAID], initial encounter
        • T39.396D Underdosing of other nonsteroidal anti-inflammatory drugs [NSAID], subsequent encounter
        • T39.396S Underdosing of other nonsteroidal anti-inflammatory drugs [NSAID], sequela
        • T39.4 Poisoning by, adverse effect of and underdosing of antirheumatics, not elsewhere classified
        • T39.4X Poisoning by, adverse effect of and underdosing of antirheumatics, not elsewhere classified
        • T39.4X1 Poisoning by antirheumatics, not elsewhere classified, accidental (unintentional)
        • T39.4X1A Poisoning by antirheumatics, not elsewhere classified, accidental (unintentional), initial encounter
        • T39.4X1D Poisoning by antirheumatics, not elsewhere classified, accidental (unintentional), subsequent encounter
        • T39.4X1S Poisoning by antirheumatics, not elsewhere classified, accidental (unintentional), sequela
        • T39.4X2 Poisoning by antirheumatics, not elsewhere classified, intentional self-harm
        • T39.4X2A Poisoning by antirheumatics, not elsewhere classified, intentional self-harm, initial encounter
        • T39.4X2D Poisoning by antirheumatics, not elsewhere classified, intentional self-harm, subsequent encounter
        • T39.4X2S Poisoning by antirheumatics, not elsewhere classified, intentional self-harm, sequela
        • T39.4X3 Poisoning by antirheumatics, not elsewhere classified, assault
        • T39.4X3A Poisoning by antirheumatics, not elsewhere classified, assault, initial encounter
        • T39.4X3D Poisoning by antirheumatics, not elsewhere classified, assault, subsequent encounter
        • T39.4X3S Poisoning by antirheumatics, not elsewhere classified, assault, sequela
        • T39.4X4 Poisoning by antirheumatics, not elsewhere classified, undetermined
        • T39.4X4A Poisoning by antirheumatics, not elsewhere classified, undetermined, initial encounter
        • T39.4X4D Poisoning by antirheumatics, not elsewhere classified, undetermined, subsequent encounter
        • T39.4X4S Poisoning by antirheumatics, not elsewhere classified, undetermined, sequela
        • T39.4X5 Adverse effect of antirheumatics, not elsewhere classified
        • T39.4X5A Adverse effect of antirheumatics, not elsewhere classified, initial encounter
        • T39.4X5D Adverse effect of antirheumatics, not elsewhere classified, subsequent encounter
        • T39.4X5S Adverse effect of antirheumatics, not elsewhere classified, sequela
        • T39.4X6 Underdosing of antirheumatics, not elsewhere classified
        • T39.4X6A Underdosing of antirheumatics, not elsewhere classified, initial encounter
        • T39.4X6D Underdosing of antirheumatics, not elsewhere classified, subsequent encounter
        • T39.4X6S Underdosing of antirheumatics, not elsewhere classified, sequela
        • T39.8 Poisoning by, adverse effect of and underdosing of other nonopioid analgesics and antipyretics, not elsewhere classified
        • T39.8X Poisoning by, adverse effect of and underdosing of other nonopioid analgesics and antipyretics, not elsewhere classified
        • T39.8X1 Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, accidental (unintentional)
        • T39.8X1A Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, accidental (unintentional), initial encounter
        • T39.8X1D Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, accidental (unintentional), subsequent encounter
        • T39.8X1S Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, accidental (unintentional), sequela
        • T39.8X2 Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, intentional self-harm
        • T39.8X2A Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, intentional self-harm, initial encounter
        • T39.8X2D Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, intentional self-harm, subsequent encounter
        • T39.8X2S Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, intentional self-harm, sequela
        • T39.8X3 Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, assault
        • T39.8X3A Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, assault, initial encounter
        • T39.8X3D Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, assault, subsequent encounter
        • T39.8X3S Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, assault, sequela
        • T39.8X4 Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, undetermined
        • T39.8X4A Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, undetermined, initial encounter
        • T39.8X4D Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, undetermined, subsequent encounter
        • T39.8X4S Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, undetermined, sequela
        • T39.8X5 Adverse effect of other nonopioid analgesics and antipyretics, not elsewhere classified
        • T39.8X5A Adverse effect of other nonopioid analgesics and antipyretics, not elsewhere classified, initial encounter
        • T39.8X5D Adverse effect of other nonopioid analgesics and antipyretics, not elsewhere classified, subsequent encounter
        • T39.8X5S Adverse effect of other nonopioid analgesics and antipyretics, not elsewhere classified, sequela
        • T39.8X6 Underdosing of other nonopioid analgesics and antipyretics, not elsewhere classified
        • T39.8X6A Underdosing of other nonopioid analgesics and antipyretics, not elsewhere classified, initial encounter
        • T39.8X6D Underdosing of other nonopioid analgesics and antipyretics, not elsewhere classified, subsequent encounter
        • T39.8X6S Underdosing of other nonopioid analgesics and antipyretics, not elsewhere classified, sequela
        • T39.9 Poisoning by, adverse effect of and underdosing of unspecified nonopioid analgesic, antipyretic and antirheumatic
        • T39.91 Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, accidental (unintentional)
        • T39.91XA Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, accidental (unintentional), initial encounter
        • T39.91XD Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, accidental (unintentional), subsequent encounter
        • T39.91XS Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, accidental (unintentional), sequela
        • T39.92 Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, intentional self-harm
        • T39.92XA Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, intentional self-harm, initial encounter
        • T39.92XD Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, intentional self-harm, subsequent encounter
        • T39.92XS Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, intentional self-harm, sequela
        • T39.93 Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, assault
        • T39.93XA Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, assault, initial encounter
        • T39.93XD Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, assault, subsequent encounter
        • T39.93XS Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, assault, sequela
        • T39.94 Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, undetermined
        • T39.94XA Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, undetermined, initial encounter
        • T39.94XD Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, undetermined, subsequent encounter
        • T39.94XS Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, undetermined, sequela
        • T39.95 Adverse effect of unspecified nonopioid analgesic, antipyretic and antirheumatic
        • T39.95XA Adverse effect of unspecified nonopioid analgesic, antipyretic and antirheumatic, initial encounter
        • T39.95XD Adverse effect of unspecified nonopioid analgesic, antipyretic and antirheumatic, subsequent encounter
        • T39.95XS Adverse effect of unspecified nonopioid analgesic, antipyretic and antirheumatic, sequela
        • T39.96 Underdosing of unspecified nonopioid analgesic, antipyretic and antirheumatic
        • T39.96XA Underdosing of unspecified nonopioid analgesic, antipyretic and antirheumatic, initial encounter
        • T39.96XD Underdosing of unspecified nonopioid analgesic, antipyretic and antirheumatic, subsequent encounter
        • T39.96XS Underdosing of unspecified nonopioid analgesic, antipyretic and antirheumatic, sequela